DTIL Latest Press Releases

-- October 8, 2026 --

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 Business Wire 7:01 AM

-- August 27, 2026 --

iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026 Business Wire 8:00 AM

-- August 24, 2026 --

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study Business Wire 6:01 AM

-- August 20, 2026 --

iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium Business Wire 8:00 AM

-- August 6, 2026 --

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire 7:01 AM

-- July 31, 2026 --

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire 7:01 AM

-- July 27, 2026 --

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones Business Wire 7:01 AM

-- July 10, 2026 --

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:01 AM

-- June 29, 2026 --

Precision BioSciences Announces Inclusion in the Russell 2000 Index Expanding Market Visibility with Institutional Investors Business Wire 7:01 AM

-- May 27, 2026 --

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 Business Wire 2:30 AM

-- May 21, 2026 --

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 Business Wire 7:01 AM

Market Data Delayed 15 Minutes